Epidemiology of Alzheimer′s disease
===================================

Alzheimer's disease (AD) is characterized by a progressive, age-related cognitive decline that ultimately results in memory loss, loss of language skills, difficulty performing routine tasks, disorientation and personality changes. Approximately 4.5 million people in the US currently suffer from AD and the incidence has been estimated at \~20% for individuals \>75 years of age \[[@r11]\]. The outlook is bleak in our aging population: disease prevalence doubles every 5 years over age of 65 and the number of affected individuals is expected to reach 13 million by 2050 \[[@r11]\]. This estimate is a conservative one, since metabolic disease may increase the risk of AD, and hypercholesterolemia, diabetes and obesity are at epidemic levels. Anti-cholinesterases are currently used to limit the progression of AD but their effectiveness is far from ideal. There is thus a critical need to understand the molecular events that underlie AD and to translate this information into more effective therapies.

Molecular pathology of AD
=========================

The two pathological hallmarks of AD are the accumulation of intracellular neurofibrillary tangles and extracellular amyloid plaques (also known as senile or neuritic plaques). The major constituent of the amyloid plaque is a peptide known as Aβ or β-amyloid \[[@r24];[@r43]\] and aggregation of this peptide is now accepted as a causative factor in the disease \[[@r10]\]. The Aβ peptide arises via cleavage of the amyloid precursor protein (APP), a glycosylated, single transmembrane protein that is a substrate for several membrane bound proteases ([Figure 1](#fig1){ref-type="fig"}). APP is first cleaved by either α- or β-secretase. This cleavage occurs in the extra-cellular or lumenal space \[[@r14];[@r16]\] to yield a 105-125 kDa secreted N-terminal fragment (APPα or APPβ), and the membrane-bound C-terminal fragment (CTF). The CTF is subsequently cleaved in the golgi-endosomal network by γ-secretase \[[@r26];[@r32]\]. This protease cleaves the CTF within the intra-membrane domain between 37-43 amino acids C-terminal to the β-secretase site. The γ-secretase products are referred to as Aβ (β-CTF) or p3 (α-CTF) as they are derived from cleavage by β/γ- or α/γ-secretases, respectively. The most common β/γ-secretase cleaved product is Aβ40 (85-95%), with Aβ42 (5-15%) being the second most abundant product. Note that the initial "choice" between α- and β-secretase has dramatic consequences for AD: cleavage by β/γ-secretase results in Aβ production whereas α-secretase cleaves within the Aβ sequence. Thus, α-secretase not only precludes formation of Aβ but results in production of the non-amyloidogenic p3 peptide. It should be noted that the sequence of the mouse Aβ peptide diverges slightly from that of humans and has less predilection to aggregate into plaques. As a result, murine models of AD were developed by transgenic expression of human APP with familial mutations.

Cholesterol and Alzheimer's
===========================

The role of cholesterol in the pathogenesis of AD came to the forefront in 2000, when two groups independently reported that subjects that were treated with 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors -- the statins -- had a significantly lower prevalence of AD. In both studies, the statins decreased AD outcome by about 70% \[[@r12];[@r42]\]. The statins act by inhibiting synthesis of mevalonic acid, a rate-limiting metabolite produced early in the cholesterol biosynthetic pathway. These findings suggest that elevated levels of cholesterol or some other biologically active precursor (e.g. farnesylpyrophosphate, geranylgeranylpyrophosphate) is associated with the development of AD. In support of a specific connection to cholesterol, four studies have reported an association between mild hypercholesterolemia and risk for AD. In earlier work, Sparks et al. \[[@r35]\] had found that subjects who died of atherosclerotic heart disease, which is associated with elevated total cholesterol, had significantly greater numbers of amyloid plaques compared to age-matched controls without atherosclerotic disease.

The cholesterol-statin-AD link has also been observed in experimental settings. Fassbender et al. \[[@r8]\] showed that guinea pigs fed large doses of simvastatin for as little as three weeks had 50% lower brain Aβ levels compared to the controls. In addition, high-cholesterol diets resulted in elevated intraneuronal Aβ levels in rabbits (Aβ sequence identical to humans), and increased plaque formation in transgenic mice expressing human APP \[[@r28];[@r34]\].

If AD arises via an increase in Aβ production/accumulation, how do alterations in cholesterol homeostasis affect the development of this disease? The answer may lie in the fact that APP/Aβ processing occurs within cholesterol-rich membrane domains, i.e. APP and the β- and γ-secretases are localized in cholesterol-rich lipid rafts \[[@r2];[@r7];[@r22];[@r29];[@r38]\].

Cholesterol homeostasis in the brain
====================================

Much like the liver, the brain expresses the machinery required for cholesterol uptake, intracellular trafficking, de novo synthesis and metabolic degradation. In the periphery, apolipoprotein AI (apoAI) and apolipoprotein E (apoE) serve as the major extracellular cholesterol acceptors. ApoE is a ligand for all members of the LDL receptor family, and directly mediates hepatic uptake of very low-density lipoprotein (VLDL). In the brain, extracellular cholesterol is transported via lipoprotein-like particles that contain astroglia- and microglia-derived apoE and apoJ \[[@r6]\]. The apoE-containing particles are endocytosed by neuronal lipoprotein receptor related protein (LRP) \[[@r41]\]. As in the periphery, these lipoprotein complexes are tran0073ported to lysosomes through endosomal pathways and ultimately other compartments via the Neiman-Pick C1 protein (NPC1) \[[@r46];[@r45]\].

It is important to note that lipoproteins cannot pass the blood-brain barrier. This has two critical implications. First, peripheral and central cholesterol pools are not readily interchangeable and are largely maintained as separate pools \[[@r15]\]. Second, the brain cannot rely on peripherally-derived cholesterol to satisfy its massive cholesterol requirements. Instead, the brain produces its own cholesterol via the standard HMG-CoA reductase-limited biosynthetic pathway. As in the liver, excess cholesterol is removed via catabolism to more polar degradation products: the liver utilizes CYP7A1 (cholesterol 7α-hydroxylase) to metabolize cholesterol to bile acids whereas the brain predominantly utilizes CYP46 (cholesterol 24-hydroxylase) to convert cholesterol to 24(S)-hydroxycholesterol \[[@r21]\]. This 24-hydroxylated metabolite can exit via the blood-brain barrier where it is further metabolized and ultimately eliminated by the liver.

APP/Aβ processing and cholesterol trafficking
=============================================

Although total cholesterol levels are tightly regulated in the brain, the precise location of individual cholesterol molecules can be highly dynamic due to endosomal uptake pathways and NPC1-mediated intracellular trafficking. Moreover, the concentration of cholesterol in different intracellular membranes is not uniform: cholesterol content increases successively from the endoplasmic reticulum to the plasma membrane, and within the plasma membrane, cholesterol is organized into distinct structural pools that include lipid rafts and caveolae. Presence of cholesterol within the membrane alters the fluidity of the surrounding membranes and impacts biological events that occur within those membranes \[[@r30]\]. Thus, dysregulation of cholesterol trafficking could contribute to AD as β/γ-secretase dependent APP/Aβ processing occurs within cholesterol-rich lipid rafts and endosomes.

Several lines of evidence support the above hypothesis. Intracellular cholesterol trafficking can be altered by expressing an NPC1 mutant. This leads to the accumulation of cholesterol in late endosomes and lysosomes. Mice expressing the mutated NPC1 show no changes in amounts of α- or β-secretase activity but exhibit increased γ-secretase activity and accumulate Aβ40 and Aβ42. Increased activity occurs without any detectable change in the amount of the PS1 subunit of γ-secretase. This suggests that changes in membrane cholesterol distribution stimulates γ-secretase activity and ultimately Aβ production \[[@r3]\]. Similarly, treatment of neurons with drugs that block cholesterol trafficking from lysosomes (U18666A, imipramine) also increased γ-secretase activity \[[@r46]\]. Enhanced γ-secretase activity was associated with abnormal localization of γ-secretase subunits (PS1 and PS2) in cholesterol sorting vesicular compartments. Thus, changes in membrane cholesterol trafficking appear to alter the activity of γ-secretase, a membrane bound APP processing enzyme.

Treatment of cells with statins and cholesterol-depleting agents suggest that cholesterol may also affect the other APP processing enzymes, i.e. α- and β-secretase. Specifically, decreasing cholesterol is associated with a rise in the non-amyloidogenic activity of α-secretase and a decrease in the amyloidogenic β-secretase activity \[[@r8];[@r16];\]. The net effect of these changes are consistent with the AD-promoting effects of cholesterol. The differential effects on α- and β-secretase may be related to the fact that α-secretase is primarily active at the cell-surface, while β-secretase (BACE) is associated with lipid rafts \[[@r16];[@r29]\]. This distinct localization of the α- and β-secretase also suggests that α-cleavage of APP could be accentuated if APP is retained longer on the cell surface. In agreement, Kojro et al. \[[@r16]\] found that depletion of membrane cholesterol increased membrane fluidity, decreased endocytosis, and was associated with increased α-cleavage and less Aβ.

Other interventions that alter cellular cholesterol transport have also been shown to alter APP cleavage. For example, overexpression of the ABCA1 lipid transporter reduced Aβ secretion in Neuro2a cells (murine neuroblastoma) expressing human APP with a swedish familial mutation (APPswe, [Figure 1](#fig1){ref-type="fig"}) \[[@r36]\]. Although ABCA1 can promote cholesterol efflux from macrophages, little cholesterol efflux was observed in these Neuro2a cells. It has been suggested that ABCA1 is primarily a phospholipid transporter; its ability to promote cholesterol efflux may be secondary to an ABCA1-mediated redistribution of cholesterol from inner to outer membrane surfaces \[[@r37]\] followed by the binding of the outer membrane cholesterol to extracellular acceptor proteins (e.g. apoAI and apoE). In adipocytes, ABCA1 has been shown to shift cholesterol from membranes to lipid droplets \[[@r19]\]. Thus, the ABCA1-dependent reduction of Aβ may be related with cholesterol redistribution rather than efflux. When viewed as a whole, this body of literature suggests that intracellular cholesterol depletion and/or redistribution has important consequences for the proteolytic processing of APP and the production of Aβ.

LXR and cholesterol homeostasis
===============================

There are a number of interesting links between the Liver X Receptors (LXRα/NR1H3 and LXRβ/NR1H2) and the above biology. LXRα was originally identified as an orphan receptor highly expressed in hepatic tissue. Subsequent studies demonstrated that LXRs are central players in cholesterol homeostasis throughout the periphery (for detailed reviews see \[[@r13];[@r47]\]. Briefly, LXRα is abundant in tissues that metabolize cholesterol including liver, intestine and macrophages ; LXRβ is ubiquitously expressed. Both receptors bind to and are activated by cholesterol derived oxysterol ligands. When activated by ligand, LXRs induce CYP7A-1 mediated cholesterol degradation in the liver (rodents) and promote cholesterol efflux from macrophages, hepatocytes and intestinal enterocytes. Enhanced efflux is mediated by LXR-dependent activation of cholesterol/lipid transporters (ABCA1, ABCG1, ABCG5 and ABCG8) and cholesterol acceptor proteins (apoE). These effects are biologically significant as synthetic LXR agonists increase plasma HDL cholesterol, stimulate cholesterol excretion into the bile and the feces, decrease hepatic cholesterol content and can reduce atherosclerotic lesions by \~50% in various murine models \[[@r4];[@r13];[@r27];[@r31];[@r44]\].

So what about LXRs and the brain? Both subtypes are expressed in the CNS at significant levels: LXRα mRNA levels range from 7-29% of that in the liver, while LXRβ levels are 2-5 fold higher in the brain than in liver. The levels of LXRα in cultured neurons and glia are 2% and 17% compared to the liver, and that for LXRβ are 1.1- and 3.8-fold, respectively \[[@r40]\]. Are these receptors functional? The answer is yes. Astrocytes treated with synthetic LXR ligands exhibit enhanced cholesterol efflux and increased expression of LXR target genes including ABCA1, ABCG1, and apoE \[[@r9];[@r17];[@r20];[@r40]\]. Lxrα/β-null mice show a variety of CNS defects including lipid accumulation, astrocyte proliferation and disorganized myelin sheaths \[[@r13]\]. These studies demonstrate that LXRs modulate cholesterol homeostasis in the CNS and are required for normal CNS function.

Is there a connection between LXRs and AD?
==========================================

The discussion above suggests that modulators of intracellular cholesterol content and/or distribution can modulate APP processing. LXR clearly meets this criterion and offers other potentially intriguing links to AD. For example, polymorphisms in apoE, an LXR-regulated gene, is the strongest predictor of late-onset AD \[[@r5]\]. CYP46 (cholesterol-24-hydroxylase) polymorphisms have also been linked to AD \[Kolsch et al., 2002; Papassotiropoulos et al., 2003\] and expression of this enzyme is shifted from neurons to glia in AD patients \[[@r1]\]. CYP46 converts cholesterol into an oxysterol ligand (24(S)-hydroxycholesterol) that can bind and activate LXRs in cultured cells. Although it remains unclear whether 24(S)-hydroxycholesterol is the active ligand that is bound to LXRs in vivo, these intriguing coincidences provide additional impetus to explore an LXR -- AD connection.

LXR agonists modulate APP/Aβ processing
=======================================

Three recent publications demonstrate that LXRs can indeed modulate proteolytic-processing of APP, albeit with conflicting conclusions. The Rebeck lab \[[@r9]\] demonstrated that LXR agonists (22(R)-hydroxycholesterol or T0901317) increased both ABCA1 expression and Aβ secretion in Neuro2A cells; exogenous cholesterol carrier was not added. The increase in Aβ was likely mediated via ABCA1 as siRNA targeting this transporter decreased Aβ production. Using two human neuroblastoma cell-lines stably expressing APPswe, the Lazo lab \[[@r17]\] also observed the expected increase in ABCA1 expression, enhanced cholesterol efflux and subsequent decrease in total cellular cholesterol. However, in sharp contrast to the previous group, LXR agonist (22(R)-hydroxycholesterol) reduced Aβ production. In these experiments, addition of apoA1 or apoE to the culture medium promoted significant cholesterol efflux, which was associated with further reduction in Aβ. Tall's group also found that LXR agonist (T0901317) enhanced ABCA1 expression and decreased Aβ production in mouse Neuro2A cells expressing human APPswe \[[@r36]\]. The reduction in Aβ was related to a decrease in β- and γ-secretase cleavage. Moreover, the decrease in Aβ could be mimicked by overexpression of wild-type ABCA1 but not by a mutant that was defective in cholesterol transport and apoAI binding. However, ABCA1-mediated reduction in Aβ was observed under conditions where there was little or no cholesterol or phospholipid efflux (i.e. without apoAI or apoE in the media). Thus unlike Rebeck's group, both Lazo and Tall's groups find that LXR inhibits Aβ by inducing ABCA1 activity. Some discussion remains as to whether the relevant activity of ABCA1 is intracellular cholesterol redistribution vs. lipid efflux. The reasons for the discrepancies among the 3 groups could be related to differences in cell lines (mouse vs. human; wild-type vs. APPswe+) and/or other methodologies.

Where do we go from here?
=========================

The potential to treat AD with a nuclear receptor ligand is quite exciting. However, given the above discrepancies, it will be critical to determine the net effect of LXR agonists on APP processing in vivo. Experiments in cell culture will be valuable in sorting through mechanistic questions but given the interactions between neurons and glia, it will be important to look at LXR effects in an in vivo setting. This is complicated by the choice of animal model. As mentioned above, the wild-type mouse does not develop AD pathology as the mouse Aβ peptide does not aggregate. This particular problem has been overcome by expressing human APP variants in several transgenic mouse models. This is not a perfect solution for many reasons, not the least of which is that cholesterol homeostasis is differentially regulated in mouse and man. Indeed, this issue has come to the forefront before for LXR. LXR agonists can raise HDL-cholesterol in several mouse models. However, mice do not express cholesteryl ester transfer protein (CETP) and the effects of LXR agonists on HDL-cholesterol are lost in transgenic mice expressing human CETP \[[@r23]\]. When it comes to cholesterol homeostasis and AD, these tales remind us to exercise more than the usual caution when extrapolating results to humans.

Another area of future interest is the relationship between peripheral and central cholesterol homeostasis and how LXR may contribute to each. As described above, it is believed that peripheral and central cholesterol pools are largely distinct. If this is the case, how does excess dietary cholesterol promote Aβ accumulation \[[@r28]\]? Similarly, some of the statins that lower AD-risk are considered relatively impermeable to the blood-brain barrier \[[@r42]\]. These findings raise the possibility of important interactions between peripheral and central cholesterol homeostasis and that peripheral targets may be viable for anti-AD therapy. The effect of peripheral vs. central effects is particularly relevant to LXR as it can directly regulate cholesterol homeostasis in both compartments.

Summary
=======

Cholesterol is proving to be an important factor in the development of AD. Population studies suggest that mild hypercholesterolemia can increase the risk of AD and decreasing cholesterol synthesis via statin administration may decrease the development of AD. Moreover, elevated cellular cholesterol content has been shown to favor production of the amyloid-β (Aβ) peptide, a pathognomic hallmark of AD. Genetic studies have suggested links between AD and several cholesterol control genes including the cholesterol acceptor ApoE (ε4 polymorphism). LXR is expressed in the brain where it modulates cholesterol homeostasis and possibly APP processing. Many questions remain, but as a master regulator of cholesterol homeostasis, LXR can be considered a potential molecular target for the treatment of AD.
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![Proteolytic processing of Aβ-Precursor Protein (APP) by α-, β-, and γ-secretase.\
(A) The single-transmembrane domain-containing full-length APP is shown along with the cleavage sites for α-, β-, and γ-secretase. (B) Non-amyloidogenic processing of APP. α-secretase cleaves APP in the extracellular space to yield the N-terminal secreted APPα fragment and the transmembrane domain-containing α-CTF. The α-CTF is then cleaved by the γ-secretase to produce the non-amyloidogenic p3 and γ-CTF fragments. (C) Amyloidogenic processing of APP. APP is cleaved by β-secretase in the extracellular domain to produce APPβ and β-CTF. The γ-secretase can cleave β-CTF at position 40 or 42 amino-acids C-terminal to the β-secretase site. Thus, the β/γ-secretase cleavage yields the amyloidogenic Aβ40 (orange) and Aβ42 peptides (orange + red), and γ-CTF.](nrs02001.f1){#fig1}
